Cereals update 234: Managing Septoria: Latest results on SDHI performance

This Arable Update outlines practical strategies for using SDHIs effectively in the field while protecting their long-term efficacy.

This Arable Update illustrates how alternating and mixing Modes of Actions and active ingredients can help sustain disease control, protect yield, and deliver financial returns.

This Update outlines the latest results on how Zymoseptoria tritici (Zt), the fungus that causes Septoria tritici blotch (STB), is responding to triazole fungicides in New Zealand wheat crops.

Farmers who save and replant legally protected cereal varieties can voluntarily declare their usage and pay a breeder royalty. The declaration system applies to all farm saved seed barley, and to farmer saved wheat if the resultant wheat crop does not pass through an end-point royalty collection agent. 

Growers are reminded to report any grass weeds that appear unfamiliar or could resemble black-grass (Alopecurus myosuroides). Early reporting remains one of our strongest tools for protecting the industry.

Following a very wet winter, FAR has received a number of requests for information around managing yellow autumn sown crops. This Arable Extra outlines ways to distinguish between nitrogen and sulphur deficiencies and provides some information to support decision making around crop management.

Wet conditions throughout winter 2025 have created challenges for growers across Canterbury. This Arable Extra addresses issues around 1) autumn sown wheat paddocks with drowned out patches and 2) considerations around sowing autumn milling wheat seed in the spring.

This Arable Update summarises yield and profitability results from 47 FAR trials since 2013, comparing programmes with and without a T0, to help guide your decision-making.

The AIMI survey of New Zealand cereal growers, as at 1 July, 2024 is now available online.

This book outlines trial-specific yields and individual cultivar disease ratings for spring sown wheat and barley cultivars included in the 2024-2025 CPT trials.